Latest Healthcare News

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Alcidion Group Limited has upgraded its full-year EBITDA guidance for FY25, now expecting earnings to exceed $4.5 million, driven by contract expansions, cost discipline, and favorable currency effects.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Mach7 Technologies has expanded its partnership with a major US radiology marketplace, signing a five-year licence amendment worth A$5 million that extends the contract by three years and adds significant value.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

Arena REIT reports a $18 million uplift in portfolio valuation driven by its early learning and healthcare assets, alongside robust occupancy and a growing development pipeline.

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

NeuroScientific Biopharmaceuticals reveals compelling clinical evidence supporting its StemSmart MSC therapy for severe steroid-refractory graft versus host disease, advancing its strategic acquisition plans.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.

Orthocell’s new study confirms Remplir™ delivers superior nerve regeneration and faster muscle recovery compared to traditional sutures, bolstering its US market rollout plans.

Race Oncology has successfully dosed the first patient with its RC220 and doxorubicin combination in a Phase 1 trial for advanced solid tumours, reporting no dose-limiting side effects. This milestone marks a key step in evaluating the safety and potential cardioprotective benefits of the novel therapy.

Amplia Therapeutics has announced a second confirmed complete response in its ACCENT trial for advanced pancreatic cancer, a notably rare achievement in this challenging disease.